Marjorie Taylor Greene's NVO trades
- The latest NVO trade was a purchase on Oct 15, 2025, when NVO closed at $56.72. It closed at $40.25 on Nov 3, 2026 (-29%).
- None of the 3 NVO purchases we can price are higher today. The median one is -28%, against +16% for the S&P 500 over the same holding periods.
Price changes use the closing price on each trade date, not the price actually paid, and ignore dividends. Filings report amounts only as ranges, so these figures show direction, not anyone's actual profit.
Marjorie Taylor Greene reported 3 NVO transactions in 3 filings with the House Clerk for 2025–2026: 3 purchases and 0 sales of Novo Nordisk A/S Common Stock, with trade dates from Aug 19, 2025 to Oct 15, 2025. The median gap between trade date and filing date is 1 day, and every trade was reported within 45 days.
- 3
- 3 / 0
- $17K – $80K
- 2025-10-20
NVO transactions reported by Marjorie Taylor Greene
| Type | Owner | ||||
|---|---|---|---|---|---|
Novo Nordisk A/S Common Stock NVO | Purchase | Self | $1,001 - $15,000 | 2025-10-20 #20033314 | |
Novo Nordisk A/S Common Stock NVO | Purchase | Self | $1,001 - $15,000 | 2025-08-29 #20030996 | |
Novo Nordisk A/S Common Stock NVO | Purchase | Self | $15,001 - $50,000 | 2025-08-20 #20030944 |
A row is a disclosure, not an execution record: the filing reports a date, a bracket, and the reported owner, but not the price, share count, or reason. Compare the trade date with the filing date to see how long the transaction stayed private.
How long disclosure took
Days from trade date to filing date for 3 rows. The STOCK Act allows 30 days from notification and no more than 45 days from the trade. A late row is a timing fact, not evidence of wrongdoing.
- 0–15 days
- 3
- 16–30 days
- 0
- 31–45 days
- 0
- Over 45 days
- 0
- Median / longest
- 1d / 5d
What Marjorie Taylor Greene's NVO filings don’t tell you
A disclosure row records a trade date, an amount bracket, and who owned the asset. It does not say why the trade was made, whether the position is still held, or anything about the business behind the ticker: revenue trends, margins, balance-sheet risk, or valuation. Those answers are in company filings, not congressional ones.
To work through a company yourself, use our stock research checklist. Members get the full version of that work: one sourced investment call a month, with the numbers and the risks that would change the view.
Members-only research
What members are reading this month
- NVIDIA’s growth has a financing bill
Sales up about 18% on the prior quarter, receivables up about 55%, supply commitments at $279 billion. What NVIDIA’s financing bill means for the price you pay.
- Citadel bought the AI fire sale. The seller had run out of time.
Up 439% in the first half, down about 67% in July: how an AI hedge fund ended up selling a roughly $16 billion stock book to Citadel at a discount.
The thesis, the numbers behind it, and what would break it. Full access is $39 a month.
Read the full researchOther members of Congress who reported NVO
More tickers reported by Marjorie Taylor Greene
Marjorie Taylor Greene and NVO: questions
Did Marjorie Taylor Greene buy or sell NVO?
House Clerk filings for 2025 and 2026 show 3 purchases and 0 sales of Novo Nordisk A/S Common Stock (NVO) reported by Marjorie Taylor Greene, between 2025-08-19 and 2025-10-15. Reported owner: Self.
How much NVO did Marjorie Taylor Greene trade?
Filings disclose brackets, not exact values. Summing the low and high ends of each bracket gives $17K – $80K across 3 transactions. Yield Theory does not estimate share counts, prices, or gains from these ranges.
When was the last NVO filing by Marjorie Taylor Greene?
The most recent filing that includes a NVO trade was filed on 2025-10-20. New filings appear in the House Clerk index and are picked up when the dataset is refreshed.
Yield Theory is not affiliated with any elected official or with Novo Nordisk A/S Common Stock. Rows are parsed from public House Clerk periodic transaction reports; amounts are reported brackets and filings can be amended. This page is educational and is not investment advice.
Don’t copy the filing. Read the thesis.
Marjorie Taylor Greene NVO disclosures are delayed, ranged, and often a spouse. Members get the monthly call that treats those rows as one input, then names catalysts, risks, and what would change the view. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included